Lv35
340 积分 2024-09-11 加入
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis
1天前
已完结
New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis
2天前
已关闭
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual
2天前
已完结
Minimally invasive, maximally impactful: minimally invasive glaucoma surgery and the changing glaucoma landscape
8天前
已关闭
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group
15天前
已完结
系统性硬化病诊疗规范
21天前
已完结
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index
21天前
已完结
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
1个月前
已完结
Editors' welcome and a working definition for a multiple sclerosis cure
1个月前
已完结
皖公网安备34019202002308
